Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average rating of “Moderate Buy” from the twenty-two research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $122.6364.

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. BTIG Research reaffirmed a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th.

Kymera Therapeutics Stock Performance

KYMR opened at $110.57 on Monday. The stock has a market capitalization of $9.10 billion, a P/E ratio of -30.97 and a beta of 1.95. Kymera Therapeutics has a 12 month low of $36.65 and a 12 month high of $130.05. The firm’s fifty day simple moving average is $96.24 and its 200 day simple moving average is $86.65.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the prior year, the company earned ($0.82) EPS. The company’s revenue was up 55.5% on a year-over-year basis. On average, equities research analysts predict that Kymera Therapeutics will post -3.28 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the sale, the director directly owned 461,794 shares of the company’s stock, valued at $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the transaction, the director owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 3,637,813 shares of company stock worth $390,253,404. 15.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KYMR. SG Americas Securities LLC grew its stake in Kymera Therapeutics by 169.1% in the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after purchasing an additional 14,261 shares in the last quarter. State of New Jersey Common Pension Fund D bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $2,610,000. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares during the last quarter. Eagle Health Investments LP acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at approximately $10,606,000. Finally, Maven Securities LTD bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $1,167,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.